Gene Review:
TIMP2 - TIMP metallopeptidase inhibitor 2
Homo sapiens
Synonyms:
CSC-21K, DDC8, Metalloproteinase inhibitor 2, TIMP-2, Tissue inhibitor of metalloproteinases 2
Esposito,
Barbour,
Murphy,
Fisher,
Magagnoli,
Cornacchia,
Kaur,
Lotrian,
Bavaria,
Mayouf,
Merli,
Ragazzini,
Benassi,
Plati,
Théret,
Boudjéma,
Clément,
Desnick,
Kazes,
Ikonomidis,
Ponticelli,
Soini,
Gorman,
Campion,
Harris,
Gamberi,
Sraer,
Dowling,
Scudellaro,
Glucksman,
Chiesa,
Boumah,
Manfrini,
Turlin,
Elalamy,
McNeilly,
Cao,
Fasoli,
Dal Canton,
Molendini,
Benassi,
Balladelli,
Ragazzini,
Gorman,
Holtz,
Kaufman,
Jones,
Zucker,
Hatmi,
Autio-Harmainen,
Bioulac-Sage,
Kaplan,
Bahabri,
Eid,
Ross,
Zeeshan,
Sewairi,
Parrilla,
Duncan,
Pazzaglia,
Ferrari,
DeClerck,
Clark,
Musso,
Conner,
Kallakury,
Sato,
Illingworth,
Mercuri,
Bertoni,
Stroud,
English,
Sheehan,
Knäuper,
Furukawa,
Picci,
Aqeel,
Spinale,
Satta,
Nguyen,
Magagnoli,
Picci,
De Mauri,
Foschi,
Meyer,
Mazzullo,
Gamberi,
Yoshizaki,
Kambouris,
Mercuri,
Martignetti,
Sheth,
Hymowitz,
Vogt,
Määttä,
Zanella,
- Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Théret, N., Musso, O., Turlin, B., Lotrian, D., Bioulac-Sage, P., Campion, J.P., Boudjéma, K., Clément, B. Hepatology (2001)
- Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. Soini, Y., Satta, J., Määttä, M., Autio-Harmainen, H. J. Pathol. (2001)
- Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Zhou, Y., Yu, C., Miao, X., Tan, W., Liang, G., Xiong, P., Sun, T., Lin, D. Carcinogenesis (2004)
- Metalloproteinase expression and prognosis in soft tissue sarcomas. Benassi, M.S., Gamberi, G., Magagnoli, G., Molendini, L., Ragazzini, P., Merli, M., Chiesa, F., Balladelli, A., Manfrini, M., Bertoni, F., Mercuri, M., Picci, P. Ann. Oncol. (2001)
- Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Ross, J.S., Kaur, P., Sheehan, C.E., Fisher, H.A., Kaufman, R.A., Kallakury, B.V. Mod. Pathol. (2003)
- Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Yang, S.W., Cody, J.J., Rivera, A.A., Waehler, R., Wang, M., Kimball, K.J., Alvarez, R.A., Siegal, G.P., Douglas, J.T., Ponnazhagan, S. Clin. Cancer Res. (2011)
- Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (Review). Yoshizaki, T., Sato, H., Furukawa, M. Oncol. Rep. (2002)
- Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Martignetti, J.A., Aqeel, A.A., Sewairi, W.A., Boumah, C.E., Kambouris, M., Mayouf, S.A., Sheth, K.V., Eid, W.A., Dowling, O., Harris, J., Glucksman, M.J., Bahabri, S., Meyer, B.F., Desnick, R.J. Nat. Genet. (2001)
- Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Saad, Z., Bramwell, V.H., Wilson, S.M., O'Malley, F.P., Jeacock, J., Chambers, A.F. Lancet (1998)
- Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. Saunders, W.B., Bohnsack, B.L., Faske, J.B., Anthis, N.J., Bayless, K.J., Hirschi, K.K., Davis, G.E. J. Cell Biol. (2006)
- Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. Wingfield, P.T., Sax, J.K., Stahl, S.J., Kaufman, J., Palmer, I., Chung, V., Corcoran, M.L., Kleiner, D.E., Stetler-Stevenson, W.G. J. Biol. Chem. (1999)
- Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Leroy, V., Monier, F., Bottari, S., Trocme, C., Sturm, N., Hilleret, M.N., Morel, F., Zarski, J.P. Am. J. Gastroenterol. (2004)
- Reconstitution of TIMP-2 expression in SH-SY5Y neuroblastoma cells by 5-azacytidine is mediated transcriptionally by NF-Y through an inverted CCAAT site. Cappabianca, L., Farina, A.R., Tacconelli, A., Mantovani, R., Gulino, A., Mackay, A.R. Exp. Cell Res. (2003)
- Frequent hypermethylation of 5' flanking region of TIMP-2 gene in cervical cancer. Ivanova, T., Vinokurova, S., Petrenko, A., Eshilev, E., Solovyova, N., Kisseljov, F., Kisseljova, N. Int. J. Cancer (2004)
- Synthesis and refolding of human TIMP-2 from E. coli, with specific activity for MMP-2. Negro, A., Onisto, M., Masiero, L., Garbisa, S. FEBS Lett. (1995)
- Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Kazes, I., Elalamy, I., Sraer, J.D., Hatmi, M., Nguyen, G. Blood (2000)
- Characterization of the role of the "MT-loop": an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. English, W.R., Holtz, B., Vogt, G., Knäuper, V., Murphy, G. J. Biol. Chem. (2001)
- Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Apte, S.S., Mattei, M.G., Olsen, B.R. Genomics (1994)
- Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kazes, I., Delarue, F., Hagège, J., Bouzhir-Sima, L., Rondeau, E., Sraer, J.D., Nguyen, G. Kidney Int. (1998)
- Tissue inhibitor of metalloproteinase-3 is up-regulated by transforming growth factor-beta1 in vitro and expressed in fibroblastic foci in vivo in idiopathic pulmonary fibrosis. García-Alvarez, J., Ramirez, R., Checa, M., Nuttall, R.K., Sampieri, C.L., Edwards, D.R., Selman, M., Pardo, A. Exp. Lung Res. (2006)
- Corneal neovascularization suppressed by TIMP2 released from human amniotic membranes. Ma, X., Li, J. Yan ke xue bao = Eye science / "Yan ke xue bao" bian ji bu (2005)
- Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model. Rao, J.S., Steck, P.A., Tofilon, P., Boyd, D., Ali-Osman, F., Stetler-Stevenson, W.G., Liotta, L.A., Sawaya, R. J. Neurooncol. (1994)
- Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli. Esposito, C., Foschi, A., Parrilla, B., Cornacchia, F., Fasoli, G., Plati, A.R., De Mauri, A., Mazzullo, T., Scudellaro, R., Dal Canton, A. Transplant. Proc. (2004)
- Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). Lafleur, M.A., Handsley, M.M., Knäuper, V., Murphy, G., Edwards, D.R. J. Cell. Sci. (2002)
- The effect of luteal "rescue" on the expression and localization of matrix metalloproteinases and their tissue inhibitors in the human corpus luteum. Duncan, W.C., McNeilly, A.S., Illingworth, P.J. J. Clin. Endocrinol. Metab. (1998)
- Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Abdel Wahab, N., Mason, R.M. Biochem. J. (1996)
- Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Pulukuri, S.M., Patibandla, S., Patel, J., Estes, N., Rao, J.S. Oncogene (2007)
- Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2. Toth, M., Bernardo, M.M., Gervasi, D.C., Soloway, P.D., Wang, Z., Bigg, H.F., Overall, C.M., DeClerck, Y.A., Tschesche, H., Cher, M.L., Brown, S., Mobashery, S., Fridman, R. J. Biol. Chem. (2000)
- Mechanisms for pro matrix metalloproteinase activation. Murphy, G., Stanton, H., Cowell, S., Butler, G., Knäuper, V., Atkinson, S., Gavrilovic, J. APMIS (1999)
- Activation of progelatinase A and progelatinase A/TIMP-2 complex by membrane type 2-matrix metalloproteinase. Kolkenbrock, H., Hecker-Kia, A., Orgel, D., Ulbrich, N., Will, H. Biol. Chem. (1997)
- Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Goldberg, G.I., Marmer, B.L., Grant, G.A., Eisen, A.Z., Wilhelm, S., He, C.S. Proc. Natl. Acad. Sci. U.S.A. (1989)
- TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface. Zucker, S., Hymowitz, M., Conner, C., DeClerck, Y., Cao, J. Exp. Cell Res. (2004)
- The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. Will, H., Atkinson, S.J., Butler, G.S., Smith, B., Murphy, G. J. Biol. Chem. (1996)
- Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. Miyamori, H., Takino, T., Kobayashi, Y., Tokai, H., Itoh, Y., Seiki, M., Sato, H. J. Biol. Chem. (2001)
- Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Kuzuya, M., Asai, T., Kanda, S., Maeda, K., Cheng, X.W., Iguchi, A. Diabetologia (2001)
- Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Ikonomidis, J.S., Jones, J.A., Barbour, J.R., Stroud, R.E., Clark, L.L., Kaplan, B.S., Zeeshan, A., Bavaria, J.E., Gorman, J.H., Spinale, F.G., Gorman, R.C. Circulation (2006)
- Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. Stetler-Stevenson, W.G., Brown, P.D., Onisto, M., Levy, A.T., Liotta, L.A. J. Biol. Chem. (1990)
- Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Noël, A., Boulay, A., Kebers, F., Kannan, R., Hajitou, A., Calberg-Bacq, C.M., Basset, P., Rio, M.C., Foidart, J.M. Oncogene (2000)
- Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Thomas, C.V., Coker, M.L., Zellner, J.L., Handy, J.R., Crumbley, A.J., Spinale, F.G. Circulation (1998)
- Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Knox, J.B., Sukhova, G.K., Whittemore, A.D., Libby, P. Circulation (1997)
- Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Takino, T., Miyamori, H., Watanabe, Y., Yoshioka, K., Seiki, M., Sato, H. Cancer Res. (2004)
- Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. Michael, M., Babic, B., Khokha, R., Tsao, M., Ho, J., Pintilie, M., Leco, K., Chamberlain, D., Shepherd, F.A. J. Clin. Oncol. (1999)
- Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Zhao, Y.G., Xiao, A.Z., Park, H.I., Newcomer, R.G., Yan, M., Man, Y.G., Heffelfinger, S.C., Sang, Q.X. Cancer Res. (2004)
- Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcomas. Benassi, M.S., Magagnoli, G., Ponticelli, F., Pazzaglia, L., Zanella, L., Gamberi, G., Ragazzini, P., Ferrari, C., Mercuri, M., Picci, P. Histol. Histopathol. (2003)